Literature DB >> 23007005

Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test.

Asuka Nakarai1, Jun Kato, Sakiko Hiraoka, Motoaki Kuriyama, Mitsuhiro Akita, Tomoko Hirakawa, Hiroyuki Okada, Kazuhide Yamamoto.   

Abstract

OBJECTIVES: Accumulating evidence has underlined the importance of mucosal healing as a treatment goal for ulcerative colitis (UC). Quantitative fecal immunochemical tests (FITs), which can rapidly quantify fecal blood with automated equipment, have been used recently to screen for colorectal neoplasia. The aim of this study is to determine whether an FIT can evaluate mucosal healing in UC.
METHODS: Feces collected from UC patients who underwent colonoscopy were examined by FITs, and results were compared with colonoscopic findings. Mucosal status was assessed using the Mayo endoscopic subscore classification. Maximum score for the colorectum in each patient was recorded.
RESULTS: Evaluated were FIT results in conjunction with 310 colonoscopies that were performed in 152 UC patients. A large majority of patients with a Mayo 0 endoscopic score had negative FIT (<100 ng/ml) results (92%), and the proportion of negative FIT results decreased with increases in the Mayo score (Mayo 1: 47%, Mayo 2: 13%, Mayo 3: 12%, P<0.0001, Cochran-Armitage trend test). When the negative FIT was defined as <100 ng/ml, the sensitivity and specificity of a negative FIT for mucosal healing (Mayo 0) were 0.92 and 0.71, respectively. When mucosal healing was defined as Mayo 0 or 1, those were 0.60 and 0.87, respectively. In addition, a positive FIT (≥100 ng/ml) predicted mucosal inflammation (Mayo 2 or 3) with sensitivity 0.87 and specificity 0.60, respectively.
CONCLUSIONS: The FIT can effectively and noninvasively evaluate mucosal healing in UC. This easy, rapid method can help evaluate and control disease activity of UC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23007005     DOI: 10.1038/ajg.2012.315

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  35 in total

1.  Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Shiho Takashima; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Toshihiro Inokuchi; Daisuke Takei; Yuki Moritou; Mitsuhiro Akita; Sakuma Takahashi; Keisuke Hori; Keita Harada; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.

Authors:  Shiho Takashima; Jun Kato; Sakiko Hiraoka; Asuka Nakarai; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada; Takehiro Tanaka; Kazuhide Yamamoto
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

4.  Evidence-based clinical practice guidelines for inflammatory bowel disease.

Authors:  Katsuyoshi Matsuoka; Taku Kobayashi; Fumiaki Ueno; Toshiyuki Matsui; Fumihito Hirai; Nagamu Inoue; Jun Kato; Kenji Kobayashi; Kiyonori Kobayashi; Kazutaka Koganei; Reiko Kunisaki; Satoshi Motoya; Masakazu Nagahori; Hiroshi Nakase; Fumio Omata; Masayuki Saruta; Toshiaki Watanabe; Toshiaki Tanaka; Takanori Kanai; Yoshinori Noguchi; Ken-Ichi Takahashi; Kenji Watanabe; Toshifumi Hibi; Yasuo Suzuki; Mamoru Watanabe; Kentaro Sugano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2018-02-10       Impact factor: 7.527

Review 5.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

6.  Noninvasive Markers of Disease Activity in Inflammatory Bowel Disease.

Authors:  Raluca Vrabie; Sunanda Kane
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

7.  Noninvasive evaluation of mucosal healing in inflammatory bowel diseases.

Authors:  Jun Kato; Sakiko Hiraoka; Asuka Nakarai; Masao Ichinose
Journal:  Clin J Gastroenterol       Date:  2012-11-28

Review 8.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

Review 9.  Are faecal markers good indicators of mucosal healing in inflammatory bowel disease?

Authors:  Gudula Jam Boon; Andrew S Day; Chris J Mulder; Richard B Gearry
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

Review 10.  Disease monitoring in inflammatory bowel disease.

Authors:  Shannon Chang; Lisa Malter; David Hudesman
Journal:  World J Gastroenterol       Date:  2015-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.